These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 10590363)
1. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group. Urban T; Chastang C; Lebas FX; Duhamel JP; Adam G; Darse J; Bréchot JM; Lebeau B Cancer; 1999 Dec; 86(11):2238-45. PubMed ID: 10590363 [TBL] [Abstract][Full Text] [Related]
2. A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma. "Petites Cellules" Group. Lebeau B; Urban T; Bréchot JM; Paillotin D; Vincent J; Leclerc P; Meekel P; L'Her P; Lebas FX; Chastang C Cancer; 1999 Oct; 86(8):1480-7. PubMed ID: 10526276 [TBL] [Abstract][Full Text] [Related]
3. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW; J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930 [TBL] [Abstract][Full Text] [Related]
4. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up. Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811 [TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995. Lee YC; McCrystal MR; Christmas TI N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564 [TBL] [Abstract][Full Text] [Related]
6. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098 [TBL] [Abstract][Full Text] [Related]
7. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group. Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149 [TBL] [Abstract][Full Text] [Related]
8. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors? Masutani M; Ochi Y; Kadota A; Akusawa H; Kisohara A; Takahashi N; Koya Y; Horie T Oncol Rep; 2000; 7(2):305-10. PubMed ID: 10671676 [TBL] [Abstract][Full Text] [Related]
9. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S; Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326 [TBL] [Abstract][Full Text] [Related]
10. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. Spiro SG; James LE; Rudd RM; Trask CW; Tobias JS; Snee M; Gilligan D; Murray PA; Ruiz de Elvira MC; O'Donnell KM; Gower NH; Harper PG; Hackshaw AK; J Clin Oncol; 2006 Aug; 24(24):3823-30. PubMed ID: 16921033 [TBL] [Abstract][Full Text] [Related]
11. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. Ardizzoni A; Favaretto A; Boni L; Baldini E; Castiglioni F; Antonelli P; Pari F; Tibaldi C; Altieri AM; Barbera S; Cacciani G; Raimondi M; Tixi L; Stefani M; Monfardini S; Antilli A; Rosso R; Paccagnella A J Clin Oncol; 2005 Jan; 23(3):569-75. PubMed ID: 15659503 [TBL] [Abstract][Full Text] [Related]
12. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920 [TBL] [Abstract][Full Text] [Related]
13. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920 [TBL] [Abstract][Full Text] [Related]
14. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. Pujol JL; Daurès JP; Rivière A; Quoix E; Westeel V; Quantin X; Breton JL; Lemarié E; Poudenx M; Milleron B; Moro D; Debieuvre D; Le Chevalier T J Natl Cancer Inst; 2001 Feb; 93(4):300-8. PubMed ID: 11181777 [TBL] [Abstract][Full Text] [Related]
15. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma. Kakolyris S; Agelidou A; Androulakis N; Tsaroucha E; Kouroussis Ch; Agelidou M; Karvounis N; Veslemes M; Christophylakis Ch; Argyraki A; Geroyianni A; Georgoulias V Lung Cancer; 2006 Jul; 53(1):59-65. PubMed ID: 16716447 [TBL] [Abstract][Full Text] [Related]
16. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma. Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768 [TBL] [Abstract][Full Text] [Related]
17. Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer. de Jong WK; Groen HJ; Koolen MG; Biesma B; Willems LN; Kwa HB; van Bochove A; van Tinteren H; Smit EF Eur J Cancer; 2007 Nov; 43(16):2345-50. PubMed ID: 17826977 [TBL] [Abstract][Full Text] [Related]
18. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). Tsuchiya R; Suzuki K; Ichinose Y; Watanabe Y; Yasumitsu T; Ishizuka N; Kato H J Thorac Cardiovasc Surg; 2005 May; 129(5):977-83. PubMed ID: 15867769 [TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy for small cell lung cancer]. Fukuoka M; Takada M; Masuda N; Furuse K; Saijo N; Ikegami H; Nishiwaki Y Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31 Suppl():225-31. PubMed ID: 7516450 [TBL] [Abstract][Full Text] [Related]
20. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results. Oshita F; Kasai T; Kurata T; Fukuda M; Yamamoto N; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N Jpn J Clin Oncol; 1995 Oct; 25(5):208-12. PubMed ID: 7474409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]